Adherence to topical therapies in actinic keratosis: A literature review

References

• Stockfleth E, Terhorst D, Braathen L, et al. Guidelines for the management of actinic keratosis. 2010. Available from http://www.ensas.ee/docs/management_of_actinic_keratoses.pdf. Accessed November 2014.
   Google Scholar
• Berlin JM. Current and emerging treatment strategies for the treatment of actinic keratosis. Clin Cosmet Investig Dermatol. 2010;3:119.
   PubMedGoogle Scholar
• Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008;18:651–9.
   PubMed Web of Science ®Google Scholar
• Dinehart SM, Nelson‐Adesokan P, Cockerell C, et al. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer 1997;79:920–3.
   PubMed Web of Science ®Google Scholar
• Marks R, Rennie G, Selwood T. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1:795–7.
   PubMed Web of Science ®Google Scholar
• Mittelbronn MA, Mullins DL, Ramos‐Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol. 1998;37:677–81.
   PubMed Web of Science ®Google Scholar
• Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Investig Dermatol. 2000;115:273–7.
   PubMed Web of Science ®Google Scholar
• Schaefer I, Augustin M, Spehr C, et al. Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J Eur Acad Dermatol Venereol. 2014;28:309–13.
   PubMed Web of Science ®Google Scholar
• Warino L, Tusa M, Camacho F, et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006;32:1045–9.
   PubMed Web of Science ®Google Scholar
• Berman B. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2012;5:111.
   PubMedGoogle Scholar
• Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16:599–606.
   PubMed Web of Science ®Google Scholar
• Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Intervent Aging. 2013;8:29–35.
   PubMed Web of Science ®Google Scholar
• National Health Service. Skin cancer (non-melanoma). 2014. Available from http://www.nhs.uk/conditions/Cancer-of-the-skin/Pages/Introduction.aspx. Accessed January 2014.
   Google Scholar
• Quaedvlieg P, Tirsi E, Thissen M, Krekels G. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16:335–9.
   PubMed Web of Science ®Google Scholar
• Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial. Cancer 2009;115:2523–30.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Fleischer Jr AB. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011;87:201–7.
   PubMed Web of Science ®Google Scholar
• electronic Medicines Compendium (eMC). Summary of product characteristics for Aldara 5% cream. 2010. Available from http://www.medicines.org.uk/emc/medicine/8/spc. Accessed November 2014.
   Google Scholar
• electronic Medicines Compendium (eMC). Summary of product characteristics for Solaraze 3% gel. 2012. Available from https://www.medicines.org.uk/emc/medicine/21229. Accessed November 2014.
   Google Scholar
• electronic Medicines Compendium (eMC). Summary of product characteristics for Zyclara 3.75% cream. 2013. Available from http://www.medicines.org.uk/emc/medicine/27323. Accessed November 2014.
   Google Scholar
• electronic Medicines Compendium (eMC). Summary of product characteristics for Efudix cream. 2014. Available from http://www.medicines.org.uk/emc/medicine/6219/SPC/Efudix+Cream. Accessed November 2014.
   Google Scholar
• electronic Medicines Compendium (eMC). Summary of product characteristics for Actikerall 5 mg/g + 100 mg/g cutaneous solution. 2014. Available from https://www.medicines.org.uk/emc/medicine/24614. Accessed November 2014.
   Google Scholar
• electronic Medicines Compendium (eMC). Summary of product characteristics for Picato 500 mcg/g gel. 2013. Available from https://www.medicines.org.uk/emc/medicine/27247. Accessed November 2014.
   Google Scholar
• electronic Medicines Compendium (eMC). Summary of product characteristics for Picato 150 mcg/g gel. 2014. Available from http://www.medicines.org.uk/emc/medicine/27290. Accessed November 2014.
   Google Scholar
• Food and Drug Adminstration. Labelling revision for Efudex. 2005. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/016831s049lbl.pdf. Accessed February 2015.
   Google Scholar
• Food and Drug Adminstration. Labelling revision for Solaraze gel. 2011. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021005s013lbl.pdf. Accessed February 2015.
   Google Scholar
• Food and Drug Adminstration. Full prescribing information for Aldara. 2010. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf. Accessed February 2015.
   Google Scholar
• Food and Drug Adminstration. Full prescribing information for Zyclara. 2012. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022483s006lbl.pdf. Accessed February 2015.
   Google Scholar
• Food and Drug Adminstration. Full prescribing information for Picato. 2012. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202833lbl.pdf. Accessed February 2015.
   Google Scholar
• Food and Drug Adminstration. Labelling revision for Carac. 2003. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20985slr004_carac_lbl.pdf. Accessed February 2015.
   Google Scholar
• Esmann S, Jemec GBE. Patients’ perceptions of topical treatments of actinic keratosis. J Dermatol Treat. 2014;25:375–9.
   PubMed Web of Science ®Google Scholar
• Wolf JE, Rigel DS. Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis. Int J Dermatol. 2013;52:1063–70.
   PubMed Web of Science ®Google Scholar
• Erntoft S, Norlin J, Pollard C, Diepgen TL. Patient adherence and non-persistence behaviour in real life Actinic Keratosis (AK) topical treatment in the UK, Germany and France. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research; 2014; Montreal.
   Google Scholar
• Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Pat Prefer Adher. 2014;8:35–41.
   Web of Science ®Google Scholar
• Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol. 2009;145:203–5.
   PubMedGoogle Scholar
• Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335–9.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714–21.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–19.
   PubMed Web of Science ®Google Scholar
• Rivers J, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94–100.
   PubMed Web of Science ®Google Scholar
• Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582–90.
   PubMed Web of Science ®Google Scholar
• Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709–13.
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.
   PubMed Web of Science ®Google Scholar
• Willis M, Erntoft S, Persson S, et al. Actinic keratosis patients are willing to pay for shorter treatment and local skin response duration and ingenol mebutate gel is likely to increase patient likelihood of successful completion of topical treatment. Value Health. 2012;15:A254.
   Google Scholar
• Peris K, Neri L, Fargnoli MC, Pellacani G. Physicians’ concerns towards prescription adherence and treatment effectiveness in the clinical management of actinic keratosis. G Ital Dermatol Venereol. 2014;149:193–8.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Peris K, Guillen C, et al. Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol. 2014;29:298–306.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.
   PubMed Web of Science ®Google Scholar
• Sabaté E. Adherence to Long-term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
   Google Scholar
• Werschler WP. Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients. J Clin Aesthet Dermatol. 2008;1:22.
   PubMedGoogle Scholar
• Hess LM, Saboda K, Malone DC, et al. Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer. Cancer Epidemiol Biomark Prev. 2005;14:2579–83.
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert‐Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5‐fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‐year follow‐up. Br J Dermatol. 2007;157:34–40.
   PubMed Web of Science ®Google Scholar
• Gibbs S, Davis T. Usage and patient experience of 5% fluorouracil cream. Clin Exp Dermatol. 2015;40:88.
   PubMed Web of Science ®Google Scholar